Lucira Health (Lucira Health) ROCE % : -298.19% (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Lucira Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lucira Health's annualized ROCE % for the quarter that ended in Sep. 2022 was -298.19%.

Lucira Health ROCE % Historical Data

The historical data trend for Lucira Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health ROCE % Chart

Lucira Health Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

ROCE %

-350.14

-83.01

-47.33

Lucira Health Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial									-53.47	-16.76	26.15	-36.28	-298.19

Lucira Health ROCE % Calculation

Lucira Health's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-64.807	/	( ( (92.703 - 8.857)	+	(240.354 - 50.331) )	/ 2 )
	=	-64.807	/	( (83.846	+	190.023)	/ 2 )
	=	-64.807	/	136.9345
	=	-47.33 %

Lucira Health's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	-503.596	/	( ( (289.036 - 57.929)	+	(189.185 - 82.521) )	/ 2 )
	=	-503.596	/	( ( 231.107	+	106.664 )	/ 2 )
	=	-503.596	/	168.8855
	=	-298.19 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

Lucira Health (OTCPK:LHDXQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lucira Health ROCE % Related Terms

Thank you for viewing the detailed overview of Lucira Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucira Health (Lucira Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1412 62nd Street, Emeryville, CA, USA, 94608

Website

https://www.lucirahealth.com

Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.

Executives

Anthony Joseph Allen	officer: Chief Operations Officer	1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding	other: CEO of 10% owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc	10 percent owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps	10 percent owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps	other: Less than 10% Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah	officer: Ex. VP &Chief Quality Officer	1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins	officer: Chief Revenue Officer	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George	officer: CFO and Treasurer	1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson	director, officer: President and Chief Executive	1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra	director, officer: Chief Technology Officer	1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar	officer: Vice President	1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley	director	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608